Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04, "The phase III ICE study: Adjuvant ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer."
Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with hormone receptor–positive early breast cancer.”
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
